Study Title
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
Protocol ID
J1S-MC-JV01
Disease (Sub Disease)
Desmoplastic Small Round Cell Tumor
Diagnosis Stage
Relapsed/refractory
Sponsor
Eli Lilly and Company
Links
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
12 Months to 29 Years
International registry ID's
NCT04145349
| Study Title | A Randomized Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed Recurrent or Refractory Desmoplastic Small Round Cell Tumor |
|---|---|
| Protocol ID | J1S-MC-JV01 |
| Disease (Sub Disease) | Desmoplastic Small Round Cell Tumor |
| Diagnosis Stage | Relapsed/refractory |
| Sponsor | Eli Lilly and Company |
| Links | https://clinicaltrials.gov/ct2/show/NCT04145349 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 02/08/2021 |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | 12 Months to 29 Years |
| International registry ID's | NCT04145349 |